Q3 2025 Revenue of $11.4 Million, an Increase of 17% over Q3 2024 83% Growth in Year-Over-Year Revenue for International Medical Cannabis International Medical sales now 56% of Total Revenue Increased Cash Balance of $10.6 Million at the end of Q3 2025 Operating Expenses Decreased 19% Year-Over-Year Management to Host Conference Call / Webcast on November 13th, 2025 at 10:00 am ETTORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and nine months ended September 30, 2025. MediPharm delivered another successful quarter of strong year-over-year revenue growth in the three months...

Announced U.S. Food and Drug Administration (FDA) Acceptance for Reviewof New Drug Application (NDA) for GTx-104 FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Neurocritical Care Annual Meeting Granted Sixth U.S. Patent Covering IV Dosing Regimen for GTx-104 PRINCETON, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) — Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights...

WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On September 14-15, 2025, the Company presented new data on the long-term neurological efficacy and safety of ALXN1840 (tiomolybdate choline) at the 150th American Neurological Association (ANA) Annual Meeting. Matthew Lorincz, M.D., Ph.D., Professor of Neurology and Co-Director of the Wilson Disease Center of Excellence at the University of Michigan delivered the poster and oral presentations. The new findings presented at ANA highlight the long-term neurological benefit of...

As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly  The FDA advised Clene to request a Type C meeting to review these further ALS biomarker data analyses The Company plans to submit a New Drug Application (NDA) in the first quarter of 2026 under an accelerated approval pathway The Company expects to have the first patient dosed in the confirmatory Phase 3 RESTORE-ALS trial of CNM-Au8 in the first half of 2026 The FDA and Clene participated in a Type B end of Phase 2 meeting in the third quarter of 2025 to discuss the Company’s MS clinical development program and ongoing plans for MS development of CNM-Au8 Cash and cash equivalents of $7.9 million as of September 30, 2025 Cash runway extended into the second quarter of 2026, including $1.2 million...

MIAMI, Nov. 13, 2025 (GLOBE NEWSWIRE) — Inter&Co Inc. (NASDAQ: INTR | B3: INBR32), the leading super app providing financial and digital commerce services to over 41 million customers, today reported its results for the third quarter of 2025. 3Q25 Highlights: Inter printed another quarter of outstanding growth across all key metrics, while maintaining its disciplined approach to sustainable profitability.Client Growth: Added a record 1.2 million new active clients in the quarter, bringing the total active client base to 24 million, a testament to the platform’s compelling value proposition. Net Income: Reached R$336 million (US$63.2 million1), representing 39% year-over-year growth, successfully balancing investments in growth with operational efficiency. Credit Expansion: The credit portfolio expanded 30% YoY, triple...

Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase 2 dose-ranging study, pending Phase 1 results and regulatory feedback 3Q 2025 private placement, together with October financings, generated approximately $25.7M in cash and cash commitments to support accelerated development of NPM-139 while securing financial position into 2027 ALAMEDA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, ultra long-acting drug implants, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. Vivani Chief Executive Officer Adam Mendelsohn,...

Third quarter 2025 GAAP net income of $4.05 million or $0.30 per basic weighted average common share and Distributable Earnings(1) of $4.12 million or $0.31 per basic weighted average common share WEST PALM BEACH, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) — Sunrise Realty Trust, Inc. (Nasdaq: SUNS) (“SUNS” or the “Company”), a lender on the Tannenbaum Capital Group (“TCG”) Real Estate platform, today announced its results for the quarter ended September 30, 2025. SUNS reported generally accepted accounting principles (“GAAP”) net income of $4.05 million or $0.30 per basic weighted average common share and Distributable Earnings of $4.12 million or $0.31 per basic weighted average common share for the third quarter of 2025. Brian Sedrish, Chief Executive Officer of SUNS, said, “Our accomplishments during the third quarter demonstrate...

Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026 CNTY-308 advancing through IND-enabling studies to support planned clinical study initiation in 2026 Estimated cash runway into 4Q 2027PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “Today we announced our iPSC derived beta islet program for T1D. We have generated a compelling preclinical data package that underscores the tremendous opportunity...

Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer Phase 2 Results Lead Company to Seek Expedited Approval Pathway in OngoingVERSATILE-003 Phase 3 Trial Design Conference Call and Webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business update, reported financial results for the third quarter ended September 30, 2025, and provided a clinical programs update. “Our request to meet with the FDA to propose an amendment to our ongoing VERSATILE-003 Phase 3 trial represents the culmination of the...

MONTREAL, Nov. 13, 2025 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor” or the “Corporation”) today announced its unaudited financial and operational results1 for the third quarter ended September 30, 2025. “This was a solid third quarter that reflects our team’s resolve to deliver strong operational results that are more representative of the usual Dynacor performance,” said Jean Martineau, President & CEO. “Despite ore supply disruptions in the first two weeks in the quarter, we are well on track to meet or beat our full-year production and financial guidance. The higher gold prices and consistent mill performance generated a number of new financial records including record quarterly EBITDA. With our strong cash flow generation and strengthened management team, we continue to cultivate shareholder value through...